Trial Profile
A Two Arm Phase II Study Assessing Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-Multiple cN2 or IIIB)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2010
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 29 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Jul 2008 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
- 20 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.